Stockscreener 앱 받기
1.00
3.85%
-0.04
Immunic Inc 주식(IMUX)의 최신 뉴스
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.80 - Defense World
Immunic CEO Daniel Vitt secures new employment terms - Investing.com
Immunic CEO Daniel Vitt secures new employment terms By Investing.com - Investing.com UK
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - Defense World
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 10.3% in November - MarketBeat
Immunic CEO Dr Daniel Vitt on successful 2024, with more to come in the year ahead - Proactive financial news
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - The Eastern Progress Online
Janus Henderson Group PLC Sells 1,974,566 Shares of Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic CSO discusses breaking the IBD stigma to mark Crohn's and Colitis Awareness Week - Proactive Investors UK
Broad Benefits Of Immunic MS Drug Could Transform Treatment - News & Insights
B. Riley Has Bearish Forecast for Immunic FY2024 Earnings - Defense World
B. Riley Estimates Immunic's FY2024 Earnings (NASDAQ:IMUX) - MarketBeat
FY2024 Earnings Estimate for Immunic Issued By HC Wainwright - Defense World
IMUXImmunic, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on Immunic (NASDAQ:IMUX) - Defense World
HC Wainwright Estimates Immunic’s Q4 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. to Participate in Investor Conference in December - The Malaysian Reserve
Immunic to present at Piper Sandler 36th Annual Healthcare Conference - Proactive Investors USA
What is HC Wainwright's Estimate for Immunic Q4 Earnings? - MarketBeat
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook - Investing.com Nigeria
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook By Investing.com - Investing.com South Africa
Immunic initiated with a Buy at H.C. Wainwright - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Average Price Target from Analysts - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.7% in October - Defense World
Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK
Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com
Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St
Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance
Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com
Immunic announces publication of IMU-856 data - Yahoo Finance
Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com
Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia
Immunic director Richard Rudick buys $100,368 in stock - Investing.com
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors UK
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA
Immunic's IMU-856 Shows Breakthrough Results in Celiac Disease Trial, Published in Lancet | IMUX Stock News - StockTitan
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - The Malaysian Reserve
Immunic (NASDAQ:IMUX) Stock Rating Lowered by StockNews.com - Defense World
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance
Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks
Immunic CEO details progress following productive third quarter - Proactive Investors Australia
Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunic: Q3 Earnings Snapshot - Milford Mirror
Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy
Immunic Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones - Proactive Investors USA
2.88%
2.65%
자본화:
|
볼륨(24시간):